Sanguinate is under clinical development by Prolong Pharmaceuticals and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Sanguinate’s likelihood of approval (LoA) and phase transition for Acute Ischemic Stroke took place on 06 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Sanguinate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Sanguinate is under development for the treatment sickle cell diseases (SCD) associated vaso-occlusive crisis and cystic fibrosis. The drug candidate is administered through intravenous route. The therapeutic candidate is a PEGylated hemoglobin. It is a Hemoglobin-based oxygen carrier (HBOC). It was under development for the treatment of ischemia-reperfusion injury in myocardial infarction, delayed graft function in recipients of kidney transplantation after donation, delayed cerebral ischemia after acute aneurysmal subarachnoid hemorrhage, end-stage renal disease and other sickle cell diseases (SCD) associated leg ulcers.
Prolong Pharmaceuticals overview
Prolong Pharmaceuticals is a clinical stage biopharmaceutical company that offers anemia care drugs. It develops products to treat several diseases and their debilitating comorbidities associated with reduced quality of life. Its Sanguinate product is in clinical development for treating sickle cell disease and other disorders caused by anemia or hypoxia and ischemia. Prolong Pharmaceuticals also has four products in development for hematology and oncology indications. The company has been associated with a number of successful pharmaceutical and biotechnology companies. Pharmaceuticals is headquartered in South Plainfield, New Jersey, the US.
Quick View Sanguinate LOA Data
|Highest Development Stage|